I haven't wait as long as other here, but i've been here good 6 months or so w/ avg of $5.
Although i have said the interim is a very high hurdle, it isn't impossible.
Here is to a surprising interim efficacy stop and all the good that follows it.
I can't imagine what is taking the IDMC so long. i can probably do the math in about 5 min if i have the data.. hint hint.
Although it was small sample, TH-302 worked great for NSCLC. If our phase II can repeat it, we will be in great shape, better than the Tarceva you just reminded us of. Thanks.
Man the waiting is killing me lol. enjoy football in the meantime. GO USA!
"MY husband's is in his lungs. He was doing a trial drug of doxorubicin and the trial drug TH-302. It was rough but he made it through. He is now on just the trial drug doing maintenance. The tumors are still shrinking and some are gone. Doctor is amazed at how well he is doing. He looks good and feels good. It is just a pain doing the chemo - one day a week for two week and one week off and then it starts again. It is promising."
She adds that doctors feel it will get approved this year.. ...
only way that can happen is if it gets halted, then FDA fast tracks it.
Oh well, never hurts to dream.
well, you do have the most recent failed phase 3 trial from ziop and that control arm lived 16.89 month. that said, the trial had different popluation, mainly being that they accepted low tumor grade. even 17month vs our phase 2 trial of 21.5 months should be enough to get it through FDA.
Im pretty confident that THLD will succeed on Pancreatic cancer trials. STS is a gift if it works out. Now PC phase 2 data was a solid trial with large trial size w/ dosage escalation showing benefits, with control arm unlike the STS.
I will hold until i see the result of pancreatic trial results. This will be multi multi bagger in 1.5 years at the lastest. more power to us if interim hits.
well now that you mention it.. it does sound a bit negative.
I will try from here to only post AWESOME and GOOD stuff.
i can see your numbers playing out.... im dumbfounded as to why WS don't see this.
I hope we repeat the phase II and that EORTC data for control happens in our trials.
Since data is not yet mature, i can see your 11 vs 19, and where final would be 12 vs 21.
eagerly waiting for the results.
Throw out the historic norm. Picasso trial contol arm of 17 month is more closer than the 10 to 12 months. Pancreatic trial will suceed. STS final data will be 16m vs 20m and barely pass the hurdlr. Hold for 1.5 mmore years
actually even if zipp control was carried over and was 16 vs 16, IDMC will say carry on.
as i said b4.. control are living longer.
I think final reasult willbe 16m vs 20 month and pass the hurdle, yet barely.
PC is the reason i am here and will continue to be here until PC results are out. Phase 2 trial of PC was very well ran.
I still wonder what idiot ran the P2 STS trial w/o control. amazing.
thanks again for the DD. For some reasons, small samples always tend to lead to higher OS.. selection bias perhaps. 9 month vs 14 should lead to approval. This will probably take 2 years to recruit and another year to see the data. Long away, yet exciting nevertheless.
Lets croxx our fingers for the interim in the meantime.. I hope we see some PR saying the 235 event has occurred.
CEO said this is a registrational trial which means if successful, it will lead to NDA. Agreed.
im still here. ... im kinda surprised we are up today lol when dow is down over 300! we are up 2 pennies.
waiting for interim result.. 2 more months.
only 8? either it will be mid double digits or low 3s, pending interim of course.
after that it's a waiting game until mid 2015. then u will see taking off to double digits before the results.
well.. think of it this way.. this way, they won't have to worry about financing if interim is a success.. just sell on market up to 30m w/o having to have secondary offering. neutral news imo.